Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Ishmael Applewhite, BSN, RN-BC, OCN
Advertisement
Articles by Ishmael Applewhite, BSN, RN-BC, OCN
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
4
Novel Adenoid Cystic Carcinoma Drug Earns FDA Breakthrough Therapy Status
5